Probing the Interactions of Phosphosulfomannans with Angiogenic Growth Factors by Surface Plasmon Resonance
- 9 September 2003
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 46 (21) , 4601-4608
- https://doi.org/10.1021/jm030180y
Abstract
The binding interactions of the phosphosulfomannan anticancer agent PI-88 (1) with the angiogenic growth factors FGF-1, FGF-2, and VEGF were studied by surface plasmon resonance (SPR) on a BIAcore 3000 biosensor. Compared with heparin, PI-88 has at least 11-fold higher affinity for FGF-1 and at least 3-fold higher affinity for VEGF, but at least 13-fold lower affinity for FGF-2. To define the structural features of PI-88 that are important for growth factor binding, several analogues, such as dephosphorylated PI-88 and a sulfated pentasaccharide, were prepared. The binding interactions of these analogues with FGF-1, FGF-2, and VEGF were similarly studied by SPR, and structure−activity relationships were determined.Keywords
This publication has 28 references indexed in Scilit:
- Drug inhibition of angiogenesisCurrent Opinion in Pharmacology, 2002
- Inhibitors of angiogenesis selectively reduce the malignant cell load in rodent models of human myeloid leukemiasLeukemia, 2002
- Characterisation of the Anticoagulant Properties of a Range of Structurally Diverse Sulfated OligosaccharidesThrombosis Research, 2001
- Molecular properties and involvement of heparanase in cancer metastasis and angiogenesisJournal of Clinical Investigation, 2001
- Antiangiogenic and antivascular therapy for cancerCurrent Opinion in Pharmacology, 2001
- Tissue Factor Pathway Inhibitor Inhibits Endothelial Cell Proliferation via Association with the Very Low Density Lipoprotein ReceptorPublished by Elsevier ,2001
- Antiangiogenic agentsCurrent Opinion in Biotechnology, 1999
- Antiangiogenic therapy of experimental cancer does not induce acquired drug resistanceNature, 1997
- Angiogenesis in cancer, vascular, rheumatoid and other diseaseNature Medicine, 1995
- Transplacental Carcinogenesis by StilbestrolNew England Journal of Medicine, 1971